


Press Release

Exentis and DKSH join forces in Asia

- Successful cooperation between DKSH and Exentis in South Korea
- On-site customer visits to present project results
- Additional Asian markets to be addressed

Stetten, Switzerland, March 6, 2025 – Exentis Group AG, provider of the world's only 3D technology platform enabling industrial large-scale manufacturing, and DKSH, a leading Swiss service provider in market expansion with approximately 28,000 employees worldwide and a strong focus on Asia, are working closely together to address the attractive South Korean market for 3D-printed applications. During joint customer visits in Seoul and Busan, including meetings with two renowned global electronics corporations, the outcomes of customer projects were successfully presented.



Successful cooperation between Exentis and DKSH to address the South Korean market



Joint on-site visit of a renowned South Korean electronics corporation

Gürsel Demircali, Chief Commercial Officer of Exentis Group AG: "During our numerous customer visits in South Korea, we received extraordinarily positive feedback. The outstanding component quality without the need for reworking, the ability to mass-produce unique ultra-fine structures, and the high degree of flexibility in the production process when modifying component designs were particularly emphasized. Based on this strong foundation, we aim to further deepen these customer relationships in the future."

DKSH and Exentis are currently in discussions to jointly expand into additional Asian markets beyond South Korea, leveraging the Exentis technology platform for the large-scale production of innovative 3D-printed applications.

About Exentis

As a solution provider, Exentis has the only proprietary 3D technology platform worldwide that allows for industrial large-scale production. Industrialized Additive Manufacturing is universally applicable. For industrial or clean room applications. With free choice of materials, such as metals, ceramics, polymers, pharmaceutical or bioprinting products. The highly flexible 3D production technology combines rework-free component geometries with advantageous cost-benefit ratios. The cold printing process in use is sustainable and conserves materials as well as resources. Our customers, the Exentis 3D community members, can choose between exclusive in-house manufacturing under license agreements or having Exentis produce millions of applications for them as a contract manufacturer.

For further information please contact:

Benjamin del Fabro

Head of Investor Relations

+41 44 520 46 00 b.delfabro@exentis-group.com

Visit us also on our website at www.exentis-group.com.